Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiro, T. P.
Right arrow Articles by Gerson, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiro, T. P.
Right arrow Articles by Gerson, S. L.
Clinical Cancer Research Vol. 7, 2309-2317, August 2001
© 2001 American Association for Cancer Research

Regular Articles

Temozolomide

The Effect of Once- and Twice-a-Day Dosing on Tumor Tissue Levels of the DNA Repair Protein O6-Alkylguanine-DNA-Alkyltransferase1

Timothy P. Spiro2, Lili Liu, Susan Majka, John Haaga, James K. V. Willson and Stanton L. Gerson

Hematology/Oncology Division, Departments of Medicine [T. P. S., L. L., J. K. V. W., S. L. G.] and Radiology [J. H.], and Ireland Cancer Center [T. P. S., L. L., S. M., J. K. V. W., S. L. G.], Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106

Temozolomide (TMZ) is a methylating agent of the imidotetrazine class, whose cytotoxic product is O6-methylguanine DNA adducts, which initiate a futile recycling of the mismatch repair pathway causing DNA strand breaks and apoptotic cell death in mismatch repair proficient cells. The DNA repair protein O6-alkylguanine DNA alkyltransferase (AGT) repairs these adducts in a suicide manner and reduces the cytotoxic action of TMZ. An antitumor threshold is reached when sufficient adducts are formed by TMZ to inactivate AGT. In this study, we evaluated the relation between TMZ dosing and AGT depletion in patients with deep visceral tumors and in peripheral blood mononuclear cells (PBMCs) to determine whether the dose of TMZ was sufficient to inactivate AGT and lead to therapeutic efficacy. To do so, we compared single dose therapy with a novel twice daily regimen in a laboratory correlate-driven Phase I dose escalation study. p.o. bolus dose TMZ 200 mg/m2 daily times five was compared with the same bolus on day 1 followed by nine doses at 12-h intervals of 50, 75, 90, or 100 mg/m2. Dose-limiting toxicity in the bid regimen (grade IV thrombocytopenia and neutropenia) was seen at 100 mg/m2, cumulative dose 1100 mg/m2, and the maximum tolerated dose was 1010 mg/m2. The degree of tumor tissue AGT activity depletion measured in biopsies before and on day 5 of therapy varied widely, between 0 (in 3 patients) and 99% (in 1), with the majority of patients (10 of 15) having 52–84% tumor AGT depletion. In contrast, AGT activity in PBMCs fell rapidly during TMZ administration to undetectable levels in all dosage groups on day 5 but did not correlate with tumor AGT depletion. TMZ pharmacokinetics were dose proportional; no accumulation occurred >5-day period in the bid regimen. Two partial responses were seen, lasting 3 and 4 months. Five additional patients achieved prolonged stabilization of disease for 4–6 monthly cycles. This is the first study to document that at maximum tolerated doses, TMZ depletes PBMC AGT but only partially and variably depletes visceral tumor AGT in most patients, even during twice daily dosing. Drug combinations or schedules designed to maximally deplete tumor AGT might improve TMZ efficacy.




This article has been cited by other articles:


Home page
 JCOHome page
M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Gururangan, C. D. Turner, C. F. Stewart, M. O'Shaughnessy, M. Kocak, T. Y. Poussaint, P. C. Phillips, S. Goldman, R. Packer, I. F. Pollack, et al.
Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study
Clin. Cancer Res., February 15, 2008; 14(4): 1124 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al.
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ranson, M. R. Middleton, J. Bridgewater, S. M. Lee, M. Dawson, D. Jowle, G. Halbert, S. Waller, H. McGrath, L. Gumbrell, et al.
Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, S. Verstovsek, D. Thomas, S. Gerson, J. Cortes, S. Faderl, A. Ferrajoli, F. Ravandi, S. Kornblau, G. Garcia-Manero, et al.
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7817 - 7824.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. F. Gajewski, J. Sosman, S. L. Gerson, L. Liu, E. Dolan, S. Lin, and E. E. Vokes
Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma
Clin. Cancer Res., November 1, 2005; 11(21): 7861 - 7865.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Paz, R. Yaya-Tur, I. Rojas-Marcos, G. Reynes, M. Pollan, L. Aguirre-Cruz, J. L. Garcia-Lopez, J. Piquer, M.-J. Safont, C. Balana, et al.
CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas
Clin. Cancer Res., August 1, 2004; 10(15): 4933 - 4938.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, U. Basso, M. Reni, F. Vastola, A. Tosoni, G. Cavallo, L. Scopece, A. J. Ferreri, M. G. Panucci, S. Monfardini, et al.
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
J. Clin. Oncol., May 1, 2004; 22(9): 1598 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran, C. Koller, et al.
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Clin. Cancer Res., May 1, 2004; 10(9): 2908 - 2917.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Danson, P. Lorigan, A. Arance, A. Clamp, M. Ranson, J. Hodgetts, L. Lomax, L. Ashcroft, N. Thatcher, and M.R. Middleton
Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma
J. Clin. Oncol., July 1, 2003; 21(13): 2551 - 2557.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Dowlati, J. Haaga, S. C. Remick, T. P. Spiro, S. L. Gerson, L. Liu, S. J. Berger, N. A. Berger, and J. K. V. Willson
Sequential Tumor Biopsies in Early Phase Clinical Trials of Anticancer Agents for Pharmacodynamic Evaluation
Clin. Cancer Res., October 1, 2001; 7(10): 2971 - 2976.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.